Analysts Set Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Price Target at $20.45

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) has earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $20.5455.

A number of equities analysts recently commented on CMPS shares. B. Riley Financial started coverage on shares of Compass Pathways in a research note on Friday, April 24th. They issued a “buy” rating and a $17.00 price objective for the company. Lifesci Capital raised shares of Compass Pathways to a “strong-buy” rating in a research note on Thursday, February 12th. Morgan Stanley decreased their price objective on shares of Compass Pathways from $18.00 to $16.00 and set an “overweight” rating for the company in a research note on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a research note on Monday, April 20th. Finally, UBS Group set a $18.00 price objective on shares of Compass Pathways in a research note on Thursday.

Compass Pathways Trading Up 5.5%

Shares of NASDAQ:CMPS opened at $9.91 on Monday. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -3.21 and a beta of 2.39. Compass Pathways has a 1-year low of $2.25 and a 1-year high of $10.21. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.77 and a current ratio of 0.77. The company has a 50 day moving average price of $6.86 and a 200 day moving average price of $6.59.

Compass Pathways (NASDAQ:CMPS) last issued its earnings results on Tuesday, March 24th. The company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.59). On average, research analysts anticipate that Compass Pathways will post -1.83 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Pathways

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Amova Asset Management Americas Inc. boosted its stake in Compass Pathways by 49.1% in the 1st quarter. Amova Asset Management Americas Inc. now owns 368,828 shares of the company’s stock worth $2,029,000 after purchasing an additional 121,491 shares during the period. Parallel Advisors LLC boosted its stake in shares of Compass Pathways by 8,450.6% during the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after buying an additional 7,183 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Compass Pathways by 49.1% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 368,828 shares of the company’s stock valued at $2,040,000 after buying an additional 121,491 shares during the period. AdvisorShares Investments LLC boosted its stake in shares of Compass Pathways by 6.9% during the 1st quarter. AdvisorShares Investments LLC now owns 246,739 shares of the company’s stock valued at $1,364,000 after buying an additional 15,829 shares during the period. Finally, North Star Investment Management Corp. boosted its stake in shares of Compass Pathways by 1,354.0% during the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after buying an additional 7,000 shares during the period. Institutional investors and hedge funds own 46.19% of the company’s stock.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.